Efficacy and Safety of Privigen in Children and Adolescents With Primary Immunodeficiency
Efficacy and Safety of Privigen in Children and Adolescents With Primary Immunodeficiency
About this item
Full title
Author / Creator
Publisher
Mary Ann Liebert, Inc. publishers
Journal title
Language
English
Formats
Publication information
Publisher
Mary Ann Liebert, Inc. publishers
Subjects
More information
Scope and Contents
Contents
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen
®
, the first 10% liquid intravenous immunoglobulin stabilized with L-proline, in patients with primary immunodeficiency. As part of a larger study, 19 children (3-11 years) and 12 adolescents (12-15 years) received Pri...
Alternative Titles
Full title
Efficacy and Safety of Privigen in Children and Adolescents With Primary Immunodeficiency
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_746086555
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_746086555
Other Identifiers
ISSN
0883-1874
E-ISSN
1557-7767
DOI
10.1089/pai.2009.0005
